中国实用外科杂志2011，Vol.31Issue(12)：1102-1103,2.
降纤维蛋白原类药物在血管疾病治疗中应用及评价
Clinical effects of defibrinogenating enzymes in the treatment of thromboembolism diseases
李晓曦1
作者信息
- 1. 中山大学附属第一医院血管甲状腺乳腺外科,广东广州 510080
- 折叠
摘要
Abstract
Antithrombotic therapy plays an important role in the treatment of thromboembolism diseases, such as peripheral arterial disease, deep vein thrombosis and acute ischemic stroke. Plasma fibrinogen is known to play an important role in the pathogenesis of venous and arterial thromboembolism, and is one of the main determinants of blood viscosity. Defibrinogenating enzyme, purified fraction derived from the venom, does not directly affect any other coagulation factors or hematological components. Defibrinogenation agents reduce rapid fibrinogen concentrations, produces anticoagulation by depleting the substrate needed for thrombus formation. Depletion of fibrinogen also decreases blood viscosity, resulting in improved blood circulation.关键词
降纤维蛋白原药物/血栓栓塞Key words
defibrinogenation agent/thromboembolism分类
医药卫生引用本文复制引用
李晓曦..降纤维蛋白原类药物在血管疾病治疗中应用及评价[J].中国实用外科杂志,2011,31(12):1102-1103,2.
